Endocannabinergic modulation of interleukin-1β in mouse hippocampus under basal conditions and after in vivo systemic lipopolysaccharide stimulation

NeuroImmunoModulation

Volumn 18, Issue 4, 2011, Pages 226-231

  Csölle, Cecília ^a   Sperlágh, Beáta ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Cannabinoids; CB1 receptor; Hippocampus; In vivo endotoxin treatment; Interleukin 1 ; Lipopolysaccharides; P2X7

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; BACTERIUM LIPOPOLYSACCHARIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; INTERLEUKIN 1BETA; PURINERGIC P2X7 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HIPPOCAMPUS; IMMUNOMODULATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ENDOCANNABINOIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, KNOCKOUT; RECEPTOR, CANNABINOID, CB1; RECEPTORS, PURINERGIC P2X7;

EID: 79952338644     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000323778     Document Type: Article

References (32)

1. Puffenbarger RA, Boothe AC, Cabral GA: Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29: 58-69. (Pubitemid 30031134)
2. Roche M, Diamond M, Kelly JP, Finn DP: In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol 2006; 181: 57-67. (Pubitemid 44827290)
3. Croci T, Landi M, Galzin AM, Marini P: Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 2003; 140: 115-122. (Pubitemid 37175837)
4. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Mechoulam R, Shohami E: Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997; 283: 918-924. (Pubitemid 27514655)
5. Laye S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzer R, Parnet P: Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression. Am J Physiol 2000; 279:R93-R98. (Pubitemid 30625421)
6. McAfoose J, Baune BT: Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009; 33: 355-366.
7. Cunningham C, Sanderson DJ: Malaise in the water maze: untangling the effects of LPS and IL-1beta on learning and memory. Brain Behav Immun 2008; 22: 1117-1127.
8. Allan SM, Tyrrell PJ, Rothwell NJ: Interleukin- 1 and neuronal injury. Nat Rev Immunol 2005; 5: 629-640.
9. Roche M, Kelly JP, O'Driscoll M, Finn DP: Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 2008; 125: 263-271.
10. Simi A, Tsakiri N, Wang P, Rothwell NJ: Interleukin- 1 and inflammatory neurodegeneration. Biochem Soc Trans 2007; 35: 1122-1126.
11. Sperlágh B, Vizi ES, Wirkner K, Illes P: P2×7 receptors in the nervous system. Prog Neurobiol 2006; 78: 327-346.
12. Witting A, Walter L, Wacker J, Moller T, Stella N: P2×7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci USA 2004; 101: 3214-3219. (Pubitemid 38327760)
13. Walter L, Dinh T, Stella N: ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. J Neurosci 2004; 24: 8068-8074. (Pubitemid 39280826)
14. Collo G, Neidhart S, Kawashima E, Kosco- Vilbois M, North RA, Buell G: Tissue distribution of the P2×7 receptor. Neuropharmacology 1997; 36: 1277-1283.
15. Perregaux D, Gabel CA: Interleukin-1 β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994; 269: 15195-15203.
16. Sanz JM, Di Virgilio F: Kinetics and mechanism of ATP-dependent IL-1 β release from microglial cells. J Immunol 2000; 164: 4893-4898. (Pubitemid 30238094)
17. Mingam R, De Smedt V, Amedee T, Bluthe RM, Kelley KW, Dantzer R, Laye S: In vitro and in vivo evidence for a role of the P2×7 receptor in the release of IL-1 β in the murine brain. Brain Behav Immun 2008; 22: 234-244.
18. Bernardino L, Balosso S, Ravizza T, Marchi N, Ku G, Randle JC, Malva JO, Vezzani A: Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2×7 receptor- mediated IL-1β release. J Neurochem 2008; 106: 271-280. (Pubitemid 351840213)
19. Csolle C, Sperlágh B: Peripheral origin of IL- 1β production in the rodent hippocampus under in vivo systemic bacterial lipopolysaccharide (LPS) challenge and its regulation by P2×7 receptors. J Neuroimmunol 2010; 219: 38-46.
20. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-404.
21. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA: Altered cytokine production in mice lacking P2×7 receptors. J Biol Chem 2001; 276: 125-132. (Pubitemid 32050297)
22. Robinson L, Goonawardena AV, Pertwee R, Hampson RE, Platt B, Riedel G: WIN55,212- 2 induced deficits in spatial learning are mediated by cholinergic hypofunction. Behav Brain Res 2010; 208: 584-592.
23. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlágh B: Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 2005; 25: 2874-2884. (Pubitemid 40389245)
24. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, Pertwee R, Makriyannis A: Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci 1999; 1:E4.
25. Mackie K: Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325.
26. Katona I, Sperlágh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF: Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19: 4544-4558. (Pubitemid 29241104)
27. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E: The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006; 22: 257-264.
28. Pertwee RG: Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307-1324.
29. Brown AJ: Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-575. (Pubitemid 350041541)
30. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101. (Pubitemid 350166046)
31. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31. (Pubitemid 43083561)
32. Ransohoff RM, Kivisäkk P, Kidd G: Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3: 569-581. (Pubitemid 37328676)